Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDPropanc Biopharma, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2025 | Q1 2026 | N/A | -$0.39 | N/A | N/A | $0 |
| 09/29/2025 | Q4 2025 | N/A | -$0.35 | N/A | N/A | $29.90 K |
| 05/15/2025 | Q3 2025 | N/A | -$12.50 | N/A | N/A | $0 |
| 02/14/2025 | Q2 2025 | N/A | -$32.22 | N/A | N/A | $0 |
| 11/14/2024 | Q1 2025 | N/A | -$287.82 | N/A | N/A | $0 |
| 09/30/2024 | Q4 2024 | N/A | -$95.95 | N/A | N/A | $0 |
| 05/15/2024 | Q3 2024 | N/A | -$296.77 | N/A | N/A | $0 |
| 02/20/2024 | Q2 2024 | N/A | -$1,028.19 | N/A | N/A | $0 |
| 11/14/2023 | Q1 2024 | N/A | -$0.04 | N/A | N/A | $0 |
| 09/28/2023 | Q4 2023 | N/A | -$0.13 | N/A | N/A | $0 |
| 05/15/2023 | Q3 2023 | N/A | -$0.42 | N/A | N/A | $0 |
| 02/09/2023 | Q2 2023 | N/A | -$0.53 | N/A | N/A | $0 |
| 11/14/2022 | Q1 2023 | N/A | -$2.13 | N/A | N/A | $0 |
| 09/28/2022 | Q4 2022 | N/A | -$5.26 | N/A | N/A | $0 |
| 05/16/2022 | Q3 2022 | N/A | -$10.55 | N/A | N/A | $0 |
| 02/14/2022 | Q2 2022 | N/A | -$18.09 | N/A | N/A | $0 |
| 11/12/2021 | Q1 2022 | N/A | -$22.31 | N/A | N/A | $0 |
| 09/28/2021 | Q4 2021 | N/A | -$83.30 | N/A | N/A | $0 |
| 05/14/2021 | Q3 2021 | N/A | -$120.98 | N/A | N/A | $0 |
| 02/12/2021 | Q2 2021 | N/A | -$448.18 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Propanc Biopharma, Inc. Earnings: FAQ's
Propanc Biopharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, February 13th, 2026 based offlast year's report dates.
The conference call for Propanc Biopharma, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Propanc Biopharma, Inc.'s latest earnings report can be read online.
Propanc Biopharma, Inc. (:PPCB) has a recorded net income of $-58,923,300.Propanc Biopharma, Inc. has generated $-14.85 earnings per share over the last four quarters.
Propanc Biopharma, Inc. (:PPCB) has a price-to-earnings ratio of -0.09 and price/earnings-to-growth ratio is -0.